In this article, I introduce two strategic additions to The Dividend Income Accelerator Portfolio: Novo Nordisk (NVO) and Novartis (NVS). These globally leading healthcare companies strengthen the portfolio’s sector and geographical diversification, reduce volatility, and enhance dividend growth potential—key elements of our risk-reward optimized investment approach.
Novo Nordisk, based in Denmark, has a P/E [FWD] Ratio of 15.99, significantly below its 5-year average of 31.22, and currently offers a Dividend Yield [FWD] of 3.55%. With a 5-Year Dividend Growth Rate [CAGR] of 21.92%, it contributes meaningfully to long-term income compounding.
Novartis, headquartered in Switzerland, has a P/E [FWD] Ratio of 14.64, well below its historical average, and offers a Dividend Yield [FWD] of 3.80%. Its strong profitability and a 5-Year Dividend Growth Rate [CAGR] of 6.44% further reinforce the portfolio’s income growth foundation.
Following these additions, our Health Care exposure increases from 7.05% to 11.28%, while international exposure grows from 13.08% to 16.58%. The portfolio now holds a Weighted Average Yield on Cost [TTM] of 4.41% and a 5-Year Dividend Growth Rate [CAGR] of 7.72%.
